Checchi Capital Advisers LLC bought a new position in Zoetis Inc (NYSE:ZTS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,196 shares of the company’s stock, valued at approximately $230,000.
A number of other hedge funds also recently bought and sold shares of ZTS. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Zoetis in the 4th quarter valued at $108,000. Steward Partners Investment Advisory LLC acquired a new position in Zoetis in the 3rd quarter worth $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the period. Shine Investment Advisory Services Inc. boosted its stake in Zoetis by 86.5% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after purchasing an additional 1,040 shares during the period. Finally, Arthur M. Cohen & Associates LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $202,000. Hedge funds and other institutional investors own 93.72% of the company’s stock.
A number of equities analysts have recently commented on the stock. BMO Capital Markets set a $78.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a research note on Monday, January 22nd. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price for the company. in a research note on Saturday, January 13th. Craig Hallum reissued a “buy” rating and issued a $85.00 price target (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Cantor Fitzgerald set a $85.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Tuesday, January 2nd. Finally, BidaskClub cut shares of Zoetis from a “hold” rating to a “sell” rating in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $73.72.
Zoetis Inc (NYSE:ZTS) traded up $0.09 during trading hours on Tuesday, hitting $73.28. 698,949 shares of the stock traded hands, compared to its average volume of 2,888,336. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $35,255.31, a P/E ratio of 38.52, a PEG ratio of 1.60 and a beta of 1.06. Zoetis Inc has a one year low of $52.00 and a one year high of $80.13.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be issued a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, January 18th. This is a boost from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 annualized dividend and a yield of 0.69%. Zoetis’s payout ratio is 26.32%.
WARNING: “Checchi Capital Advisers LLC Purchases Shares of 3,196 Zoetis Inc (NYSE:ZTS)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/13/3196-shares-in-zoetis-inc-zts-purchased-by-checchi-capital-advisers-llc.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.